HM2 (ATCC® HB-8587)

Organism: human (T cell); human (T cell leukemia)  /  Cell Type: hybridoma: helper T lymphocyte  /  Disease: Leukemia,hepatitis

Permits and Restrictions

View Permits

Organism human (T cell); human (T cell leukemia)
Cell Type hybridoma: helper T lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 2 Cells Contain RETROVIRUS

Biosafety  classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease Leukemia,hepatitis
Applications
The cells produce a SSF that specifically inhibits T cell dependent immune functions.
NOTE: this line should be handled with care since one of the fusion partners was derived from a patient with AIDS.
Hepatitis B virus precautions are recommended by the depositor.
Derivation
T cells from a patient with acquired immunodeficiency syndrome (AIDS) were fused with K37.3.2 human T cell leukemia cells.
NOTE: this line should be handled with care since one of the fusion partners was derived from a patient with AIDS.
Clinical Data
T cells from a patient with acquired immunodeficiency syndrome (AIDS) were fused with K37.3.2 human T cell leukemia cells.
NOTE: this line should be handled with care since one of the fusion partners was derived from a patient with AIDS.
Antigen Expression
Leu 3a; CD4
Genes Expressed
soluble suppression factor (SSF),Leu 3a; CD4
Cellular Products
soluble suppression factor (SSF)
Comments
T cells from a patient with acquired immunodeficiency syndrome (AIDS) were fused with K37.3.2 human T cell leukemia cells.
The cells produce a SSF that specifically inhibits T cell dependent immune functions.
NOTE: this line should be handled with care since one of the fusion partners was derived from a patient with AIDS.
Hepatitis B virus precautions are recommended by the depositor.
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Complete Growth Medium
Culture medium: RPMI 1640, 90%; fetal bovine serum, 10%.
Subculturing
Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
Name of Depositor Cornell Res. Fndn., Inc.
U.S. Patent Number
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished.
References

Laurence JC. Human T cell hybridomas which produce immunosuppressive factors. US Patent 4,665,032 dated May 12 1987

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
References

Laurence JC. Human T cell hybridomas which produce immunosuppressive factors. US Patent 4,665,032 dated May 12 1987